Publication | Closed Access

Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial

Single ArmAdvanced Brafv600-mutant MelanomaMedicineMelanomaPathologyImmune Checkpoint InhibitorMek InhibitorCancer TreatmentOncologyRadiation OncologyMolecular OncologySkin Cancer